Page last updated: 2024-11-13

sr1001

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

SR1001: a selective RORalpha and RORgamma inverse agonist; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID44241473
CHEMBL ID3094388
CHEBI ID187817
SCHEMBL ID2489597
MeSH IDM0558432

Synonyms (29)

Synonym
SR-03000001001-1
SR-03000001001-2
sr-03000001001
CHEBI:187817
sr 1001
n-[5-[[4-(1,1,1,3,3,3-hexaluoro-2-hydroxypropan-2-yl)phenyl]sulamoyl]-4-methyl-1,3-thiazol-2-yl]acetamide
bdbm50444338
S6724
CHEMBL3094388 ,
CS-3963
SCHEMBL2489597
1335106-03-0
sr1001
n-[4-methyl-5-[[[4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]amino]sulfonyl]-2-thiazolylacetamide
sr-1001
HY-13421
AKOS024458386
sr1001, >=98% (hplc)
ozbsskgbkholga-uhfffaoysa-n
n-(5-(n-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)sulfamoyl)-4-methylthiazol-2-yl)acetamide
BS-14916
n-[5-[[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]sulfamoyl]-4-methyl-1,3-thiazol-2-yl]acetamide
gtpl10143
BCP09202
EX-A4866
D71041
A858112
n-(5-{[4-(1,1,1,3,3,3-hexafluoro-2-hydroxy-2-propanyl)phenyl]sulfamoyl}-4-methyl-1,3-thiazol-2-yl)acetamide
DTXSID801348120

Research Excerpts

Treatment

ExcerptReferenceRelevance
"For SR1001 treatment, the mice were injected intraperitoneally (i.p.) twice a day with vehicle or SR1001, which was dissolved in a dimethylsulfoxide (DMSO) solution."( Targeting Th17-IL-17 Pathway in Prevention of Micro-Invasive Prostate Cancer in a Mouse Model.
Burris, TP; Cunningham, DM; Ge, D; Huang, F; Liu, S; Ma, L; You, Z; Zhang, Q, 2017
)
0.94
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
sulfonamideAn amide of a sulfonic acid RS(=O)2NR'2.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Nuclear receptor ROR-alphaHomo sapiens (human)Ki0.17200.13200.15200.1720AID1177724
Nuclear receptor ROR-gammaHomo sapiens (human)IC50 (µMol)2.00000.06001.93579.4100AID1059103
Nuclear receptor ROR-gammaHomo sapiens (human)Ki0.11100.05100.08900.1110AID1177723
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Nuclear receptor ROR-gammaHomo sapiens (human)EC50 (µMol)0.91100.02000.70359.0000AID1059102
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (32)

Processvia Protein(s)Taxonomy
positive regulation of transcription by RNA polymerase IINuclear receptor ROR-alphaHomo sapiens (human)
angiogenesisNuclear receptor ROR-alphaHomo sapiens (human)
regulation of DNA-templated transcriptionNuclear receptor ROR-alphaHomo sapiens (human)
xenobiotic metabolic processNuclear receptor ROR-alphaHomo sapiens (human)
nitric oxide biosynthetic processNuclear receptor ROR-alphaHomo sapiens (human)
regulation of smoothened signaling pathwayNuclear receptor ROR-alphaHomo sapiens (human)
positive regulation of vascular endothelial growth factor productionNuclear receptor ROR-alphaHomo sapiens (human)
regulation of glucose metabolic processNuclear receptor ROR-alphaHomo sapiens (human)
regulation of steroid metabolic processNuclear receptor ROR-alphaHomo sapiens (human)
cerebellar Purkinje cell differentiationNuclear receptor ROR-alphaHomo sapiens (human)
cerebellar granule cell precursor proliferationNuclear receptor ROR-alphaHomo sapiens (human)
intracellular receptor signaling pathwayNuclear receptor ROR-alphaHomo sapiens (human)
circadian regulation of gene expressionNuclear receptor ROR-alphaHomo sapiens (human)
cellular response to sterolNuclear receptor ROR-alphaHomo sapiens (human)
cholesterol homeostasisNuclear receptor ROR-alphaHomo sapiens (human)
muscle cell differentiationNuclear receptor ROR-alphaHomo sapiens (human)
positive regulation of circadian rhythmNuclear receptor ROR-alphaHomo sapiens (human)
regulation of macrophage activationNuclear receptor ROR-alphaHomo sapiens (human)
negative regulation of canonical NF-kappaB signal transductionNuclear receptor ROR-alphaHomo sapiens (human)
negative regulation of fat cell differentiationNuclear receptor ROR-alphaHomo sapiens (human)
positive regulation of DNA-templated transcriptionNuclear receptor ROR-alphaHomo sapiens (human)
cGMP metabolic processNuclear receptor ROR-alphaHomo sapiens (human)
negative regulation of inflammatory responseNuclear receptor ROR-alphaHomo sapiens (human)
triglyceride homeostasisNuclear receptor ROR-alphaHomo sapiens (human)
cellular response to interleukin-1Nuclear receptor ROR-alphaHomo sapiens (human)
cellular response to tumor necrosis factorNuclear receptor ROR-alphaHomo sapiens (human)
cellular response to hypoxiaNuclear receptor ROR-alphaHomo sapiens (human)
T-helper 17 cell differentiationNuclear receptor ROR-alphaHomo sapiens (human)
regulation of transcription by RNA polymerase IINuclear receptor ROR-alphaHomo sapiens (human)
negative regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
xenobiotic metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of glucose metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of steroid metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
intracellular receptor signaling pathwayNuclear receptor ROR-gammaHomo sapiens (human)
circadian regulation of gene expressionNuclear receptor ROR-gammaHomo sapiens (human)
cellular response to sterolNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of circadian rhythmNuclear receptor ROR-gammaHomo sapiens (human)
regulation of fat cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of DNA-templated transcriptionNuclear receptor ROR-gammaHomo sapiens (human)
adipose tissue developmentNuclear receptor ROR-gammaHomo sapiens (human)
T-helper 17 cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (17)

Processvia Protein(s)Taxonomy
RNA polymerase II transcription regulatory region sequence-specific DNA bindingNuclear receptor ROR-alphaHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingNuclear receptor ROR-alphaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificNuclear receptor ROR-alphaHomo sapiens (human)
transcription coregulator bindingNuclear receptor ROR-alphaHomo sapiens (human)
transcription corepressor bindingNuclear receptor ROR-alphaHomo sapiens (human)
transcription coactivator bindingNuclear receptor ROR-alphaHomo sapiens (human)
DNA bindingNuclear receptor ROR-alphaHomo sapiens (human)
DNA-binding transcription factor activityNuclear receptor ROR-alphaHomo sapiens (human)
protein bindingNuclear receptor ROR-alphaHomo sapiens (human)
beta-catenin bindingNuclear receptor ROR-alphaHomo sapiens (human)
oxysterol bindingNuclear receptor ROR-alphaHomo sapiens (human)
zinc ion bindingNuclear receptor ROR-alphaHomo sapiens (human)
sequence-specific DNA bindingNuclear receptor ROR-alphaHomo sapiens (human)
ligand-activated transcription factor activityNuclear receptor ROR-alphaHomo sapiens (human)
nuclear receptor activityNuclear receptor ROR-alphaHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
protein bindingNuclear receptor ROR-gammaHomo sapiens (human)
oxysterol bindingNuclear receptor ROR-gammaHomo sapiens (human)
zinc ion bindingNuclear receptor ROR-gammaHomo sapiens (human)
ligand-activated transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
sequence-specific double-stranded DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
nuclear receptor activityNuclear receptor ROR-gammaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (5)

Processvia Protein(s)Taxonomy
nucleusNuclear receptor ROR-alphaHomo sapiens (human)
nucleoplasmNuclear receptor ROR-alphaHomo sapiens (human)
nucleolusNuclear receptor ROR-alphaHomo sapiens (human)
chromatinNuclear receptor ROR-alphaHomo sapiens (human)
nucleusNuclear receptor ROR-alphaHomo sapiens (human)
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
nucleoplasmNuclear receptor ROR-gammaHomo sapiens (human)
nuclear bodyNuclear receptor ROR-gammaHomo sapiens (human)
chromatinNuclear receptor ROR-gammaHomo sapiens (human)
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (9)

Assay IDTitleYearJournalArticle
AID1177724Binding affinity to RORa-LBD (unknown origin) by radioligand binding assay2014Journal of medicinal chemistry, Jul-24, Volume: 57, Issue:14
Modulators of the nuclear receptor retinoic acid receptor-related orphan receptor-γ (RORγ or RORc).
AID1059101Inverse agonist activity at N-terminal 6xHis-tagged human RORc ligand binding domain (241 to 486) expressed in bacterial expression system assessed as inhibition of SRC1 co-activator peptide recruitment after 3 hrs by TR-FRET analysis relative to apo-RORc2013Bioorganic & medicinal chemistry letters, Dec-15, Volume: 23, Issue:24
Structure-based design of substituted hexafluoroisopropanol-arylsulfonamides as modulators of RORc.
AID1059103Displacement of [3H2]-25-hydroxycholesterol from N-terminal 6xHis-tagged human RORc ligand binding domain (241 to 486) expressed in bacterial expression system after 3 hrs by scintillation counting analysis2013Bioorganic & medicinal chemistry letters, Dec-15, Volume: 23, Issue:24
Structure-based design of substituted hexafluoroisopropanol-arylsulfonamides as modulators of RORc.
AID1139699Antagonist activity at human LXR-alpha expressed in HEK293 cells assessed as inhibition of T0901317-induced effect after 16 hrs by luciferase reporter gene assay2014Bioorganic & medicinal chemistry, May-01, Volume: 22, Issue:9
Structure-activity relationship-guided development of retinoic acid receptor-related orphan receptor gamma (RORγ)-selective inverse agonists with a phenanthridin-6(5H)-one skeleton from a liver X receptor ligand.
AID1139701Antagonist activity at human LXR-beta expressed in HEK293 cells assessed as inhibition of T0901317-induced effect after 16 hrs by luciferase reporter gene assay2014Bioorganic & medicinal chemistry, May-01, Volume: 22, Issue:9
Structure-activity relationship-guided development of retinoic acid receptor-related orphan receptor gamma (RORγ)-selective inverse agonists with a phenanthridin-6(5H)-one skeleton from a liver X receptor ligand.
AID1059102Inverse agonist activity at N-terminal 6xHis-tagged human RORc ligand binding domain (241 to 486) expressed in bacterial expression system assessed as inhibition of SRC1 co-activator peptide recruitment after 3 hrs by TR-FRET analysis2013Bioorganic & medicinal chemistry letters, Dec-15, Volume: 23, Issue:24
Structure-based design of substituted hexafluoroisopropanol-arylsulfonamides as modulators of RORc.
AID1177723Binding affinity to RORc-LBD (unknown origin) by radioligand binding assay2014Journal of medicinal chemistry, Jul-24, Volume: 57, Issue:14
Modulators of the nuclear receptor retinoic acid receptor-related orphan receptor-γ (RORγ or RORc).
AID1139698Agonist activity at human LXR-alpha expressed in HEK293 cells after 16 hrs by luciferase reporter gene assay2014Bioorganic & medicinal chemistry, May-01, Volume: 22, Issue:9
Structure-activity relationship-guided development of retinoic acid receptor-related orphan receptor gamma (RORγ)-selective inverse agonists with a phenanthridin-6(5H)-one skeleton from a liver X receptor ligand.
AID1139700Agonist activity at human LXR-beta expressed in HEK293 cells after 16 hrs by luciferase reporter gene assay2014Bioorganic & medicinal chemistry, May-01, Volume: 22, Issue:9
Structure-activity relationship-guided development of retinoic acid receptor-related orphan receptor gamma (RORγ)-selective inverse agonists with a phenanthridin-6(5H)-one skeleton from a liver X receptor ligand.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (22)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's17 (77.27)24.3611
2020's5 (22.73)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 28.07

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index28.07 (24.57)
Research Supply Index3.14 (2.92)
Research Growth Index4.56 (4.65)
Search Engine Demand Index38.53 (26.88)
Search Engine Supply Index2.48 (0.95)

This Compound (28.07)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (9.09%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other20 (90.91%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]